🎉 M&A multiples are live!
Check it out!

Arovella Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Arovella Therapeutics and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Arovella Therapeutics Overview

About Arovella Therapeutics

Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.


Founded

1999

HQ

Australia
Employees

14

Website

arovella.com

Financials

LTM Revenue $1.5M

LTM EBITDA n/a

EV

$67.4M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Arovella Therapeutics Financials

Arovella Therapeutics has a last 12-month revenue of $1.5M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Arovella Therapeutics achieved revenue of $11K and an EBITDA of -$5.5M.

Arovella Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Arovella Therapeutics valuation multiples based on analyst estimates

Arovella Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.3M $11K XXX XXX XXX
Gross Profit $0.1M $0.1M XXX XXX XXX
Gross Margin 22% 1190% XXX XXX XXX
EBITDA -$5.9M -$5.5M XXX XXX XXX
EBITDA Margin -2297% -51144% XXX XXX XXX
Net Profit -$5.5M -$6.4M XXX XXX XXX
Net Margin -2124% -59890% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Arovella Therapeutics Stock Performance

As of March 14, 2025, Arovella Therapeutics's stock price is AUD 0 (or $0).

Arovella Therapeutics has current market cap of AUD 118M (or $74.9M), and EV of AUD 107M (or $67.4M).

See Arovella Therapeutics trading valuation data

Arovella Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$67.4M $74.9M XXX XXX XXX XXX $-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Arovella Therapeutics Valuation Multiples

As of March 14, 2025, Arovella Therapeutics has market cap of $74.9M and EV of $67.4M.

Arovella Therapeutics's trades at 45.4x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Arovella Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Arovella Therapeutics and 10K+ public comps

Arovella Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $67.4M XXX XXX XXX
EV/Revenue 64.3x XXX XXX XXX
EV/EBITDA -11.4x XXX XXX XXX
P/E -12.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -12.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Arovella Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Arovella Therapeutics Valuation Multiples

Arovella Therapeutics's NTM/LTM revenue growth is 56%

Arovella Therapeutics's revenue per employee for the last fiscal year averaged $1K, while opex per employee averaged $0.5M for the same period.

Over next 12 months, Arovella Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Arovella Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Arovella Therapeutics and other 10K+ public comps

Arovella Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -96% XXX XXX XXX XXX
EBITDA Margin -564% XXX XXX XXX XXX
EBITDA Growth -7% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -508% XXX XXX XXX XXX
Revenue per Employee $1K XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 16300% XXX XXX XXX XXX
R&D Expenses to Revenue 39620% XXX XXX XXX XXX
Opex to Revenue 63696% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Arovella Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Arovella Therapeutics M&A and Investment Activity

Arovella Therapeutics acquired  XXX companies to date.

Last acquisition by Arovella Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Arovella Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Arovella Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Arovella Therapeutics

When was Arovella Therapeutics founded? Arovella Therapeutics was founded in 1999.
Where is Arovella Therapeutics headquartered? Arovella Therapeutics is headquartered in Australia.
How many employees does Arovella Therapeutics have? As of today, Arovella Therapeutics has 14 employees.
Is Arovella Therapeutics publicy listed? Yes, Arovella Therapeutics is a public company listed on ASX.
What is the stock symbol of Arovella Therapeutics? Arovella Therapeutics trades under ALA ticker.
When did Arovella Therapeutics go public? Arovella Therapeutics went public in 2002.
Who are competitors of Arovella Therapeutics? Similar companies to Arovella Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Arovella Therapeutics? Arovella Therapeutics's current market cap is $74.9M
What is the current revenue of Arovella Therapeutics? Arovella Therapeutics's last 12-month revenue is $1.5M.
What is the current EV/Revenue multiple of Arovella Therapeutics? Current revenue multiple of Arovella Therapeutics is 45.4x.
What is the current revenue growth of Arovella Therapeutics? Arovella Therapeutics revenue growth between 2023 and 2024 was -96%.
Is Arovella Therapeutics profitable? Yes, Arovella Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.